Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034554 · ClinicalTrials.gov registry record · Phase 1
Study of gp75 Vaccine in Patients With Stage III and IV Melanoma
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00034554 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 31 participants.
The verdict
NCT00034554, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
Up to 24 patients with stage III or stage IV melanoma will be enrolled. Patients who are currently disease-free but at high risk for relapse are also eligible. Patients will receive vaccinations of gp75 at assigned dose levels. Patients who exhibit serologic and stable/clinical response are eligible to receive booster vaccinations. Patients will be evaluated for safety and efficacy throughout the duration of the study. In this study, the optimal biologically effective dose is defined as the lowest dose of gp75 that results in the production of anti-gp75 antibodies.
Interventions
- BIOLOGICAL gp75 DNA vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2002-03 |
| Est. Completion | 2004-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00034554
The ClinicalTrials.gov registry entry for NCT00034554 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which gp75 DNA vaccine is the first listed.
NCT00034554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00034554 about?
NCT00034554 is a clinical study titled "Study of gp75 Vaccine in Patients With Stage III and IV Melanoma". Up to 24 patients with stage III or stage IV melanoma will be enrolled. Patients who are currently disease-free but at high risk for relapse are also eligible. Patients will receive vaccinations of gp75 at assigned dose levels. Patients who exhibit serologic and stable/clinical response are eligible...
What is the current status of trial NCT00034554?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2002-03. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00034554?
The interventions under investigation include: gp75 DNA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00034554?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.